Advertisement

Topics

Bayer, Loxo Oncology update clinical data from larotrectinib paediatric phase I SCOUT trial

05:49 EST 6 Dec 2017 | PharmaBiz

Bayer and Loxo Oncology, Inc., a biopharmaceutical company based in Stamford, Connecticut, US, announced updated clinical data from the larotrectinib (LOXO─101) paediatric phase I SCOUT trial (NCT02637687).

Original Article: Bayer, Loxo Oncology update clinical data from larotrectinib paediatric phase I SCOUT trial

NEXT ARTICLE

More From BioPortfolio on "Bayer, Loxo Oncology update clinical data from larotrectinib paediatric phase I SCOUT trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...